KRM Ayurveda Ltd
KRMAYURVEDKRM Ayurveda Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: profits are rising, but only 0% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (26 weeks in) while the P/E sits at the 46th percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +124.2% year on year, and 0% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
KRM Ayurveda Ltd trades at ₹283, in a confirmed uptrend and 26 weeks into that stage. That is +25.1% against its own 200-day average. It sits at 86% of a 52-week range of ₹169 to ₹302. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 4 straight weeks.
Today the stock is in a confirmed uptrend — week 26 of stage 2, confirmed. At ₹283 it trades +25.1% versus its 200-day average and sits at 86% of its 52-week range (₹169–₹302).
Against the market, two honest reads. Cumulative: over the last 6 months the stock moved +67% while the NIFTY 500 moved +1% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 4 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
KRM Ayurveda Ltd trades at 23.9× P/E, mid-range by its own standards (46th percentile). Its long-run median P/E is 25.0×, measured across 0.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 23.9× is mid-range by its own standards (46th percentile), against a long-run median of 25.0× measured over 0.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
KRM Ayurveda Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +32.5% | +4.6% | — | — |
| Profit | +66.7% | +35.7% | — | — |
| EPS | −98.8% | −87.7% | — | — |
4-Factor Sector Score
59.0/100 — rank 6 of 7 in Hospitals/Medical Services · 38% evidence confidence · provisional, ranked below fully-evidenced peers
KRM Ayurveda Ltd scores 59.0 out of 100 against the 7 companies it is compared with in Hospitals/Medical Services, ranking 6. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 18.5 + 19 + 11.5 + 10 = 59. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
KRM Ayurveda Ltd reported ₹32.3 Cr of revenue in the Jun 26 quarter, +31.0% year on year. Over 3 years it has compounded at 4.6% a year. The last full year, FY26, came in at ₹102 Cr. The last four reported quarters add to ₹137 Cr.
FY26 revenue came in at ₹102 Cr (+32.5% on the year), capping 3 years at 4.6% compound. The latest quarter (Jun 26) printed ₹32.3 Cr, +31.0% year on year.
Pace check: the last four quarters averaged +4.8% growth against the decade's 4.6% — the current year is running in line with its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
KRM Ayurveda Ltd's operating margin is 37.2% in the Jun 26 quarter, +12.0 percentage points against the same quarter a year ago. Across the last four quarters the operating margin has moved +16.2 percentage points. Across 4 fiscal years the operating margin has ranged 11.0% to 30.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 37.2%, +12.0 pp against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged 11.0%–30.0%.
Why the margin moved: operating margin went +16.5 pp year on year while gross margin went +5.4 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
KRM Ayurveda Ltd earned ₹9.1 Cr of net profit in the Jun 26 quarter, +124.2% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹20.0 Cr. The 3-year compound rate is 35.7%. That is 28.1% of the quarter's revenue. The same quarter a year earlier earned ₹5.0 Cr.
Jun 26 profit was ₹9.1 Cr, +124.2% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹20.0 Cr (+66.7%), and the 3-year compound rate is 35.7%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 0% of KRM Ayurveda Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹1.0 Cr of operating cash against ₹20.0 Cr of profit. After ₹0.0 Cr of capital spending, ₹1.0 Cr was left as free cash.
FY26: operating cash of ₹1.0 Cr against reported profit of ₹20.0 Cr, leaving free cash of ₹1.0 Cr after ₹0.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 0% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 0%: the cash cycle stretched 282 days between FY23 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 282 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
KRM Ayurveda Ltd's cash conversion cycle runs 227 days in FY26, up from −55 days in FY23. Capital spending ran ₹6.0 Cr over the last 3 years. At FY26 sales of ₹102 Cr each day of that cycle holds about ₹0.3 Cr, so roughly ₹63.0 Cr sits inside the business at any moment.
FY26: debtors at 82 days, inventory at 225 days — roughly 7.4 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 227 days, looser than FY23's −55.
The full loop: cash goes out to suppliers and production on day 0; stock waits 225 days to sell; customers pay about 82 days after that; and suppliers themselves are paid at 80 days — netting out to the 227-day cycle.
In money terms: at FY26 sales of ₹102 Cr, each day of the cycle holds about ₹0.3 Cr — so the 227-day loop keeps roughly ₹63.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹6.0 Cr over the last 3 fiscal years against ₹3.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
KRM Ayurveda Ltd earns a ROCE of 35% in FY26. That is up from a trough of 22% in FY24. Return on invested capital clears the cost of that capital by +15.9 percentage points, so growth here adds value rather than only size. The wiring behind it is 19.6% net margin on 0.84× asset turns.
FY26 ROCE is 35%, recovered from a FY24 trough of 22% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 19.6% net margin × 0.84× asset turns × 1.07× balance-sheet leverage ≈ 17.6% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 27.9% − 12.0% = a +15.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
KRM Ayurveda Ltd carries ₹0.0 Cr of borrowings against ₹114 Cr of equity in FY26, a debt-to-equity of 0.00. Operating profit covers the interest bill 10×. Over 3 years borrowings went from ₹20.0 Cr to ₹0.0 Cr. Capital spending ran ₹6.0 Cr across the last 3 of those years.
FY26: borrowings of ₹0.0 Cr against equity of ₹114 Cr — a debt-to-equity of 0.00. Operating profit covers the interest bill 10×. Over 3 years borrowings went from ₹20.0 Cr to ₹0.0 Cr while capital spending ran ₹6.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of KRM Ayurveda Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — .
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
KRM Ayurveda Ltd: the Z-score reads 35.61. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 35.61 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 35.61.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Unihealth Hospitals LtdUNIHEALTH | 69.3/100Thin evidence · provisional56% evidence | LEADER | 19.0/35 Revenue — · PAT — · OPM change -4 pp 26% evidence | 19.8/25 ROCE 24.5% · OPM 34% 95% evidence | 10.5/20 P/E 41.9× · PEG — 15% evidence | 20.0/20 RS sector 30.2% · RS bench 77.7% · 1Y 321%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 19.8 + 10.5 + 20 = 69.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Dr Agarwals Health Care LtdAGARWALEYE | 55.1/100Mixed-positive evidence69% evidence | BREAKING OUT | 29.1/35 Revenue 22.9% · PAT 42.3% · OPM change 2 pp 95% evidence | 9.6/25 ROCE 11.1% · OPM 28% 76% evidence | 8.5/20 P/E 109× · PEG — 15% evidence | 7.9/20 RS sector -38.8% · RS bench 4.9% · 1Y 14%7 of 11 weeks ahead 70% evidence |
| Exact sum: 29.1 + 9.6 + 8.5 + 7.9 = 55.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Nephrocare Health Services LtdNEPHROPLUS | 53.5/100Thin evidence · provisional55% evidence | FADING | 19.9/35 Revenue — · PAT — · OPM change 0 pp 48% evidence | 9.6/25 ROCE 15.3% · OPM 21% 100% evidence | 14.0/20 P/E 82.3× · PEG 0.04 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —10 of 12 weeks ahead 0% evidence |
| Exact sum: 19.9 + 9.6 + 14 + 10 = 53.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Gujarat Kidney & Super Speciality LtdGKSL | 49.3/100Mixed-negative evidence60% evidence | ASLEEP | 18.2/35 Revenue 100% · PAT 36.7% · OPM change -32.1 pp 95% evidence | 11.6/25 ROCE 14.5% · OPM 24.4% 95% evidence | 9.5/20 P/E 68× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —9 of 12 weeks ahead 0% evidence |
| Exact sum: 18.2 + 11.6 + 9.5 + 10 = 49.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Gaudium IVF and Women Health LtdGAUDIUMIVF | 48.7/100Mixed-negative evidence60% evidence | BREAKING OUT | 13.1/35 Revenue 16.3% · PAT 10.6% · OPM change -16.5 pp 95% evidence | 14.6/25 ROCE 29.3% · OPM 12.5% 95% evidence | 11.0/20 P/E 38.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —6 of 6 weeks ahead 0% evidence |
| Exact sum: 13.1 + 14.6 + 11 + 10 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6KRM Ayurveda Ltdthis pageKRMAYURVED | 59.0/100Thin evidence · provisional38% evidence | TURNING | 18.5/35 Revenue — · PAT — · OPM change 12 pp 32% evidence | 19.0/25 ROCE 35.3% · OPM 37.2% 95% evidence | 11.5/20 P/E 23.9× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —11 of 12 weeks ahead 0% evidence |
| Exact sum: 18.5 + 19 + 11.5 + 10 = 59 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Park Medi World LtdPARKHOSPS | 52.9/100Thin evidence · provisional38% evidence | BREAKING OUT | 17.6/35 Revenue — · PAT — · OPM change 0 pp 45% evidence | 15.3/25 ROCE 19.3% · OPM 26% 76% evidence | 10.0/20 P/E 43.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 17.6 + 15.3 + 10 + 10 = 52.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is KRM Ayurveda Ltd's share price today?
KRM Ayurveda Ltd trades at ₹283. The company is valued at ₹601 Cr. The stock sits at 86% of its 52-week range of ₹169–₹302, +25.1% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 26 weeks in. — as of 14 August 2026.
What were KRM Ayurveda Ltd's latest quarterly results?
KRM Ayurveda Ltd reported revenue of ₹32.3 Cr and net profit of ₹9.1 Cr for the Jun 26 quarter. Revenue rose 31.0% and profit rose 124.2% year on year. Earnings per share were ₹4.27. The operating margin was 37.2%, 12.0 pp higher than a year earlier. — as of 14 August 2026.
What is KRM Ayurveda Ltd's revenue?
KRM Ayurveda Ltd reported revenue of ₹32.3 Cr in the Jun 26 quarter, +31.0% year on year. For the full FY26 fiscal year, revenue was ₹102 Cr (+32.5%). Over the last 3 years revenue compounded at 4.6% a year. — as of 14 August 2026.
What is KRM Ayurveda Ltd's profit?
KRM Ayurveda Ltd earned ₹9.1 Cr of net profit in the Jun 26 quarter, +124.2% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹20.0 Cr. The operating margin ran 37.2% in the latest quarter. — as of 14 August 2026.
What is KRM Ayurveda Ltd's market cap?
KRM Ayurveda Ltd's market capitalisation is ₹601 Cr at a share price of ₹283. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 14 August 2026.
What is KRM Ayurveda Ltd's P/E ratio?
KRM Ayurveda Ltd trades at a P/E of 23.9×, at the 46th percentile of its own 1-year range, against a long-run median of 25.0×. This is a comparison with the stock's own history, not a value call — as of 14 August 2026.
Does KRM Ayurveda Ltd pay a dividend?
No — KRM Ayurveda Ltd has recorded a dividend payout of 0% of profit in each of its last 4 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 14 August 2026.
Is KRM Ayurveda Ltd overvalued?
On its own history, KRM Ayurveda Ltd looks mid-range: its P/E of 23.9× sits at the 46th percentile of its 1-year range (long-run median 25.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 14 August 2026.
Is KRM Ayurveda Ltd growing?
Yes — KRM Ayurveda Ltd is growing: latest-quarter revenue +31.0% year on year, profit +124.2%, and the margin +12.0 pp at 37.2%. The 3-year compound rates are 4.6% (revenue) and 35.7% (profit). The earnings engine currently reads: improving — as of 14 August 2026.
How is KRM Ayurveda Ltd performing?
KRM Ayurveda Ltd is in a confirmed uptrend, 26 weeks in. Its latest quarter's revenue rose 31.0% and profit rose 124.2% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 14 August 2026.
Is KRM Ayurveda Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 26 of stage 2), trading +25.1% versus its 200-day average and at 86% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 14 August 2026.
Is KRM Ayurveda Ltd beating the market?
On recent form, yes — KRM Ayurveda Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 4 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 6 months the stock moved +67% against the NIFTY 500's +1% — ahead of the index over the full window. — as of 14 August 2026.
Will KRM Ayurveda Ltd's share price go up?
This page publishes no price forecast for KRM Ayurveda Ltd. What it measures instead: the share price is ₹283, the price is in a confirmed uptrend 26 weeks in. Its P/E of 23.9× sits at the 46th percentile of its own 1-year range. — as of 14 August 2026.
Who owns KRM Ayurveda Ltd?
Promoters hold 69.2% of KRM Ayurveda Ltd, foreign institutions 3.9%, domestic institutions 3.3% and the public 23.6% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 14 August 2026.
Does KRM Ayurveda Ltd have too much debt?
No — KRM Ayurveda Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill 10×. FY26 borrowings were ₹0.0 Cr against equity of ₹114 Cr. The returns on this page are earned, not borrowed — as of 14 August 2026.
What is KRM Ayurveda Ltd's capex?
KRM Ayurveda Ltd spent ₹6.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹0.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 14 August 2026.
What is KRM Ayurveda Ltd's cash flow?
KRM Ayurveda Ltd generated ₹1.0 Cr of operating cash flow in FY26 and ₹1.0 Cr of free cash flow after ₹0.0 Cr of capital spending. Reported profit that year was ₹20.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 14 August 2026.
Is KRM Ayurveda Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 0% of KRM Ayurveda Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹1.0 Cr against reported profit of ₹20.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 14 August 2026.
How financially safe is KRM Ayurveda Ltd?
On the balance sheet, the Z-score reads 35.61 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 14 August 2026.
Where is KRM Ayurveda Ltd in its business cycle?
KRM Ayurveda Ltd's FY26 operating margin was 30.0%, against a 4-year band of 11.0%–30.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 37.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 14 August 2026.
What could break the KRM Ayurveda Ltd story?
The sharpest disagreement: profits are rising, but only 0% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 14 August 2026.
Is KRM Ayurveda Ltd a stock worth studying right now?
This is not investment advice. The machine read: KRM Ayurveda Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 14 August 2026.